Compare Funko Inc (FNKO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Merck & Co., Inc. — how do they compare? Funko Inc trades at $5.89 (market cap $332.33M), while Merck & Co., Inc. trades at $133.65 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 968.2× Funko Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | MRK | |
|---|---|---|
Market Cap | $332.33M | $321.77B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $131.84 |
52-Week Low | $2.65 | $77.60 |
Enterprise Value | $552.98M | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.19, up 5.27% with bullish technical signals and strong recent earnings beats. The company shows improving fundamentals with Q2 2026 revenue growth of 7% to $207.7 million and raised EBITDA guidance. Despite negative net margins, the stock trades at attractive valuation multiples with P/S of 0.35 and EV/EBITDA of 6.46. Recent management changes and successful product launches support positive momentum.
Outlook remains cautiously optimistic with analyst consensus leaning toward hold/buy. Key opportunities include continued execution of the 'Make Culture POP!' strategy and margin improvement, while risks include persistent negative profitability and competitive pressures in the collectibles market. The stock presents value potential if operational improvements continue.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
